From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Executive Summary

• Avant Technologies highlights its cell‑encapsulation JV and a new anti‑aging therapy program, underscoring large market opportunities in diabetes and age‑related diseases.
• Vertex reports first pediatric clinical data for CASGEVY® showing 12 months freedom from vaso‑occlusive crises in sickle‑cell patients and transfusion independence in beta‑thalassemia patients, with regulatory filings planned for early 2026.
• Novo Nordisk submits a supplemental NDA for a higher‑dose Wegovy® (7.2 mg) that achieved ~20 % average weight loss in Phase 3 data, seeking accelerated review.
• CRISPR Therapeutics reports strong global patient interest in CASGEVY®, completion of Phase 1 CTX310® data for cardiovascular disease, and projects >US$100 M CASGEVY revenue this year.
• Sernova completes the first tranche of a CAD 874,600 private placement to fund its Phase 1/2 diabetes Cell Pouch trial, including incorporation of a novel immunomodulatory antibody.

Key Details

• Avant Technologies (AVAI) – Announces joint venture Insulinova with SGAustria to develop encapsulated insulin‑producing cells; also details 50/50 JV Klothonova with Austrianova targeting circulating a‑Klotho restoration for anti‑aging therapies.
• Vertex Pharmaceuticals (VRTX) – Pediatric CASGEVY data: 4 SCD patients free of vaso‑occlusive crises ≥12 months; 6 TDT patients transfusion‑independent ≥12 months. Dosing complete for ages 5‑11; regulatory submissions slated H1 2026; program to expand to ages 2‑4.
• Novo Nordisk (NVO) – Supplemental NDA filed for Wegovy® 7.2 mg. STEP UP Phase 3 results: mean weight loss 20.7 % vs 17.5 % (2.4 mg) and 2.4 % (placebo); 33.2 % of patients achieved ≥25 % loss. Review under FDA’s National Priority Voucher, expected 1‑2 month timeline.
• CRISPR Therapeutics (CRSP) – ~300 patient referrals to CASGEVY authorized centers; ~165 first cell collections completed (50 in Q3 2025). Positive Phase 1 CTX310® data presented at AHA Scientific Sessions and published in NEJM, showing durable triglyceride & LDL reductions after single IV dose. Projects >US$100 M CASGEVY revenue for 2025 with growth in 2026.
• Sernova Biotherapeutics (SVA) – Closed first private‑placement tranche: 5,466,250 units @ CAD 0.16/unit = CAD 874,600 gross proceeds. Units include one common share + one warrant (exercise $0.40, 36‑month term). Proceeds earmarked for general working capital and launch of Cohort C in Cell Pouch Phase 1/2 trial, incorporating investigational antibody tegoprubart.

Notable Quotes

• Chris Winter, CEO, Avant Technologies: “Cell encapsulation is a game‑changer… offering the potential of restoring natural glucose control and dramatically improving patients’ quality of life.”
• Carmen Bozic, M.D., EVP & CMO, Vertex: “These results … demonstrate the transformative potential of CASGEVY… we are excited to begin global regulatory filings in the first half of next year.”
• Anna Windle, Ph.D., SVP Clinical Development, Novo Nordisk: “If approved, semaglutide 7.2 mg would bring patients a new option for greater weight loss potential…”
• Samarth Kulkarni, Ph.D., CEO, CRISPR Therapeutics: “CASGEVY momentum continues to build globally… positive Phase 1 data … highlight the breadth and potential of our platform.”
• Jonathan Rigby, CEO, Sernova: “This financing … significantly strengthens our balance sheet as we enter an exciting new phase of clinical development.”